Allosteric drugs and mutations: chances, challenges, and necessity.

Allosteric drugs have become an indispensable toolbox of rapidly developing precision medicine, having already established reputation of advantages over traditional medicines. Allosteric mechanisms are also widely involved in the action of SNPs and latent cancer drivers, and can be used in fine and specific tuning of biologics, providing a great potential in diagnostics and therapy. We discuss here major targets for prospected allosteric medicines, currently available allosteric compounds, and drug-candidates at different stages of research and (pre)clinical trials. We describe our computational model of the comprehensive allosteric control of protein activity, outlining the ways of implementing it in pharmacological applications. Finally, we formulate outstanding questions and discuss feasible directions in the work on allosteric drugs and mutations.

[1]  Ekaterina D Kots,et al.  Allosteric Control of N-Acetyl-Aspartate Hydrolysis by the Y231C and F295S Mutants of Human Aspartoacylase , 2018, J. Chem. Inf. Model..

[2]  Shaoyong Lu,et al.  Discovery of hidden allosteric sites as novel targets for allosteric drug design. , 2017, Drug discovery today.

[3]  Ali Jazayeri,et al.  Fragment and Structure-Based Drug Discovery for a Class C GPCR: Discovery of the mGlu5 Negative Allosteric Modulator HTL14242 (3-Chloro-5-[6-(5-fluoropyridin-2-yl)pyrimidin-4-yl]benzonitrile). , 2015, Journal of medicinal chemistry.

[4]  Sudarshan Rajagopal,et al.  Biased signalling: from simple switches to allosteric microprocessors , 2018, Nature Reviews Drug Discovery.

[5]  Bryan L Roth,et al.  Discovery of new GPCR ligands to illuminate new biology. , 2017, Nature chemical biology.

[6]  R. Nussinov,et al.  Allostery in Disease and in Drug Discovery , 2013, Cell.

[7]  Patrik Johansson,et al.  Structural insight into allosteric modulation of protease-activated receptor 2 , 2017, Nature.

[8]  Ke Ma,et al.  Balancing Protein Stability and Activity in Cancer: A New Approach for Identifying Driver Mutations Affecting CBL Ubiquitin Ligase Activation. , 2016, Cancer research.

[9]  M. Beltramello,et al.  Conformational Occlusion of Blockade Antibody Epitopes, a Novel Mechanism of GII.4 Human Norovirus Immune Evasion , 2018, mSphere.

[10]  Aashish Manglik,et al.  Allosteric Nanobodies Reveal the Dynamic Range and Diverse Mechanisms of GPCR Activation , 2016, Nature.

[11]  R. Nussinov,et al.  'Latent drivers' expand the cancer mutational landscape. , 2015, Current opinion in structural biology.

[12]  Enrico Guarnera,et al.  Toward Comprehensive Allosteric Control over Protein Activity. , 2019, Structure.

[13]  V. Hilser,et al.  Dynamic allostery can drive cold adaptation in enzymes , 2018, Nature.

[14]  A. Schlessinger,et al.  Advances and Challenges in Rational Drug Design for SLCs. , 2019, Trends in pharmacological sciences.

[15]  Yvonne Jones,et al.  Mechanism of inhibition of HIV-1 reverse transcriptase by non-nucleoside inhibitors , 1995, Nature Structural Biology.

[16]  Yurii S. Moroz,et al.  Ultra-large library docking for discovering new chemotypes , 2019, Nature.

[17]  M. Humphries,et al.  Ligand-induced Epitope Masking , 2016, The Journal of Biological Chemistry.

[18]  Enrico Guarnera,et al.  On the perturbation nature of allostery: sites, mutations, and signal modulation. , 2019, Current opinion in structural biology.

[19]  D. Kern,et al.  Allosteric modulation of a human protein kinase with monobodies , 2019, Proceedings of the National Academy of Sciences.

[20]  Frank von Delft,et al.  An expanded allosteric network in PTP1B by multitemperature crystallography, fragment screening, and covalent tethering , 2018, eLife.

[21]  T. Steitz,et al.  Crystal structure at 3.5 A resolution of HIV-1 reverse transcriptase complexed with an inhibitor. , 1992, Science.

[22]  Shuguang Yuan,et al.  New Binding Sites, New Opportunities for GPCR Drug Discovery. , 2019, Trends in biochemical sciences.

[23]  R. Nussinov,et al.  Is allostery an intrinsic property of all dynamic proteins? , 2004, Proteins.

[24]  Shaoyong Lu,et al.  The chemical diversity and structure-based discovery of allosteric modulators for the PIF-pocket of protein kinase PDK1 , 2019, Journal of enzyme inhibition and medicinal chemistry.

[25]  W. Goddard,et al.  Activation mechanism of the G protein-coupled sweet receptor heterodimer with sweeteners and allosteric agonists , 2017, Proceedings of the National Academy of Sciences.

[26]  T. Hirokawa,et al.  Unnatural Tripeptides as Potent Positive Allosteric Modulators of T1R2/T1R3. , 2019, ACS medicinal chemistry letters.

[27]  J. Lindstrom,et al.  Discovery of an intrasubunit nicotinic acetylcholine receptor–binding site for the positive allosteric modulator Br-PBTC , 2019, The Journal of Biological Chemistry.

[28]  Zhongming Zhao,et al.  Proteome-Scale Investigation of Protein Allosteric Regulation Perturbed by Somatic Mutations in 7,000 Cancer Genomes. , 2017, American journal of human genetics.

[29]  George A. Cortina,et al.  Predicting allostery and microbial drug resistance with molecular simulations. , 2018, Current opinion in structural biology.

[30]  Mechanism of the allosteric activation of the ClpP protease machinery by substrates and active-site inhibitors , 2019, Science Advances.

[31]  Shaoyong Lu,et al.  Allosteric Modulator Discovery: From Serendipity to Structure-Based Design. , 2019, Journal of medicinal chemistry.

[32]  Dahlia R. Weiss,et al.  Structure-based discovery of selective positive allosteric modulators of antagonists for the M2 muscarinic acetylcholine receptor , 2018, Proceedings of the National Academy of Sciences.

[33]  F. Gervasio,et al.  Bidirectional Allosteric Communication between the ATP-Binding Site and the Regulatory PIF Pocket in PDK1 Protein Kinase. , 2016, Cell chemical biology.

[34]  Simon Mitternacht,et al.  SPACER: server for predicting allosteric communication and effects of regulation , 2013, Nucleic Acids Res..

[35]  Arthur Christopoulos,et al.  Allosteric modulators of GPCRs: a novel approach for the treatment of CNS disorders , 2009, Nature Reviews Drug Discovery.

[36]  J. Wess,et al.  Activation and allosteric modulation of a muscarinic acetylcholine receptor , 2013, Nature.

[37]  Arthur Christopoulos,et al.  Structural insights into G-protein-coupled receptor allostery , 2018, Nature.

[38]  Ruth Nussinov,et al.  Drugging Ras GTPase: a comprehensive mechanistic and signaling structural view. , 2016, Chemical Society reviews.

[39]  Kathryn A. Porter,et al.  Kinase Atlas: Druggability Analysis of Potential Allosteric Sites in Kinases. , 2019, Journal of medicinal chemistry.

[40]  Igor N. Berezovsky,et al.  Reversing allosteric communication: From detecting allosteric sites to inducing and tuning targeted allosteric response , 2018, PLoS Comput. Biol..

[41]  F. Lombardo,et al.  Discovery of Asciminib (ABL001), an Allosteric Inhibitor of the Tyrosine Kinase Activity of BCR-ABL1. , 2018, Journal of medicinal chemistry.

[42]  Simon Mitternacht,et al.  Coherent Conformational Degrees of Freedom as a Structural Basis for Allosteric Communication , 2011, PLoS Comput. Biol..

[43]  Igor N Berezovsky,et al.  Thermodynamics of allostery paves a way to allosteric drugs. , 2013, Biochimica et biophysica acta.

[44]  Enrico Guarnera,et al.  Allosteric sites: remote control in regulation of protein activity. , 2016, Current opinion in structural biology.

[45]  C. Brooks,et al.  Conservation of coactivator engagement mechanism enables small-molecule allosteric modulators , 2018, Proceedings of the National Academy of Sciences.

[46]  Frank Eisenhaber,et al.  Toward Allosterically Increased Catalytic Activity of Insulin-Degrading Enzyme against Amyloid Peptides. , 2017, Biochemistry.

[47]  P. Sexton,et al.  Allosteric modulation of G protein-coupled receptors. , 2004, Current pharmaceutical design.

[48]  Enrico Guarnera,et al.  Insulin-Degrading Enzyme in the Fight against Alzheimer's Disease. , 2018, Trends in pharmacological sciences.

[49]  J. Wells,et al.  Searching for new allosteric sites in enzymes. , 2004, Current opinion in structural biology.

[50]  D. Danley,et al.  Discovery of a human liver glycogen phosphorylase inhibitor that lowers blood glucose in vivo. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[51]  M. Barahona,et al.  Prediction of allosteric sites and mediating interactions through bond-to-bond propensities , 2016, Nature Communications.

[52]  Shuguang Yuan,et al.  Advancing Drug Discovery via Artificial Intelligence. , 2019, Trends in pharmacological sciences.

[53]  Athi N. Naganathan,et al.  Modulation of allosteric coupling by mutations: from protein dynamics and packing to altered native ensembles and function , 2018, Current opinion in structural biology.

[54]  Igor N. Berezovsky,et al.  Structure-Based Statistical Mechanical Model Accounts for the Causality and Energetics of Allosteric Communication , 2016, PLoS Comput. Biol..

[55]  S. Schwartz,et al.  Atomic resolution probe for allostery in the regulatory thin filament , 2016, Proceedings of the National Academy of Sciences.

[56]  Amanda E. Wakefield,et al.  Analysis of tractable allosteric sites in G protein-coupled receptors , 2019, Scientific Reports.

[57]  K. Lindorff-Larsen,et al.  Allosteric modulation of the sarcoplasmic reticulum Ca2+ ATPase by thapsigargin via decoupling of functional motions. , 2019, Physical chemistry chemical physics : PCCP.

[58]  O. Khersonsky,et al.  Incorporating an allosteric regulatory site in an antibody through backbone design , 2017, Protein science : a publication of the Protein Society.

[59]  V. Bolanos-Garcia,et al.  Pseudokinases: From Allosteric Regulation of Catalytic Domains and the Formation of Macromolecular Assemblies to Emerging Drug Targets , 2019, Catalysts.

[60]  Marc Therrien,et al.  Inhibition of RAS function through targeting an allosteric regulatory site. , 2017, Nature chemical biology.

[61]  M. Mohammadi,et al.  A Conserved Allosteric Pathway in Tyrosine Kinase Regulation. , 2019, Structure.

[62]  Ruth Nussinov,et al.  Review: Precision medicine and driver mutations: Computational methods, functional assays and conformational principles for interpreting cancer drivers , 2019, PLoS Comput. Biol..

[63]  Igor N. Berezovsky,et al.  AlloSigMA: allosteric signaling and mutation analysis server , 2017, Bioinform..

[64]  M. Congreve,et al.  Applying Structure-Based Drug Design Approaches to Allosteric Modulators of GPCRs. , 2017, Trends in pharmacological sciences.

[65]  Mark B. Gerstein,et al.  Leveraging protein dynamics to identify cancer mutational hotspots using 3D structures , 2019, Proceedings of the National Academy of Sciences.

[66]  Ali Jazayeri,et al.  Intracellular allosteric antagonism of the CCR9 receptor , 2016, Nature.

[67]  E. Papadopoulos,et al.  The Role of Dynamics and Allostery in the Inhibition of the eIF4E/eIF4G Translation Initiation Factor Complex. , 2016, Angewandte Chemie.

[68]  Simon Mitternacht,et al.  Binding Leverage as a Molecular Basis for Allosteric Regulation , 2011, PLoS Comput. Biol..

[69]  J. Changeux,et al.  Allosteric Modulation as a Unifying Mechanism for Receptor Function and Regulation , 2016, Cell.

[70]  Enrico Guarnera,et al.  On the Allosteric Effect of nsSNPs and the Emerging Importance of Allosteric Polymorphism. , 2019, Journal of molecular biology.

[71]  M. Jordan,et al.  Microtubules as a target for anticancer drugs , 2004, Nature Reviews Cancer.

[72]  Igor N Berezovsky,et al.  Towards descriptor of elementary functions for protein design. , 2019, Current opinion in structural biology.

[73]  N. Reyes,et al.  Structure and allosteric inhibition of excitatory amino acid transporter 1 , 2017, Nature.

[74]  Cody J. Wenthur,et al.  Drugs for allosteric sites on receptors. , 2014, Annual review of pharmacology and toxicology.

[75]  A Universal Pattern in the Percolation and Dissipation of Protein Structural Perturbations. , 2017, The journal of physical chemistry letters.

[76]  J. Yeo,et al.  Role of the IgE variable heavy chain in FcεRIα and superantigen binding in allergy and immunotherapy. , 2019, The Journal of allergy and clinical immunology.

[77]  N. Paparoidamis,et al.  IDENTIFICATION OF A NOVEL ALLOSTERIC MODULATOR OF THE HUMAN DOPAMINE TRANSPORTER. , 2019, ACS chemical neuroscience.

[78]  Shaoyong Lu,et al.  Emerging roles of allosteric modulators in the regulation of protein‐protein interactions (PPIs): A new paradigm for PPI drug discovery , 2019, Medicinal research reviews.

[79]  Simon Mitternacht,et al.  A geometry-based generic predictor for catalytic and allosteric sites. , 2011, Protein engineering, design & selection : PEDS.